Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies ; day:28 ; month:3 ; year:2024 ; pages:1-12
European radiology ; (28.3.2024), 1-12
- Urheber
-
Hamm, Charlie A.
Baumgärtner, Georg L.
Padhani, Anwar R.
Froböse, Konrad P.
Dräger, Franziska
Beetz, Nick L.
Savic, Lynn J.
Posch, Helena
Lenk, Julian
Schallenberg, Simon
Maxeiner, Andreas
Cash, Hannes
Günzel, Karsten
Hamm, Bernd
Asbach, Patrick Rainer
Penzkofer, Tobias
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00330-024-10700-z
- URN
-
urn:nbn:de:101:1-2407112111207.393371744649
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hamm, Charlie A.
- Baumgärtner, Georg L.
- Padhani, Anwar R.
- Froböse, Konrad P.
- Dräger, Franziska
- Beetz, Nick L.
- Savic, Lynn J.
- Posch, Helena
- Lenk, Julian
- Schallenberg, Simon
- Maxeiner, Andreas
- Cash, Hannes
- Günzel, Karsten
- Hamm, Bernd
- Asbach, Patrick Rainer
- Penzkofer, Tobias
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biomarkers for prostate cancer: prostate-specific antigen and beyond
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery
Biomarkers for prostate cancer: prostate-specific antigen and beyond
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy
Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery
Biomarkers for prostate cancer: prostate-specific antigen and beyond
The Additional Value of Free Prostate Specific Antigen to the Battery of Age-Dependent Prostate-Specific Antigen, Prostate-Specific Antigen Density and Velocity
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy
Prostate-specific antigen-based screening: controversy and guidelines
Prostate-specific antigen testing accuracy in community practice
Prostate cancer risk prediction based on clinical factors and prostate-specific antigen
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma
Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy